Plasma γ′/γ fibrinogen ratio, a marker of arterial thrombotic activity: A new potential cardiovascular risk factor?

Blood Coagulation and Fibrinolysis

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Drouet, L ^a   Paolucci, F ^b   Pasqualini, N ^b   Laprade, M ^b   Ripoll, L ^a   Mazoyer, E ^a   Bal Dit Sollier, C ^a   Vanhove, N ^c  

^a HÔPITAL LARIBOISIÈRE   (France)

^b SANOFI   (France)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; FIBRINOPEPTIDES GAMMA;

BLOOD; BLOOD CLOTTING; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; RISK FACTOR; THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD COAGULATION; FIBRINOGEN; HUMANS; MYOCARDIAL ISCHEMIA; RISK FACTORS; THROMBOSIS;

EID: 0033069413     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Meade TW, Mellows S, Brozovic M, et al. Haemostatic funtion and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 6: 533-537.
2. Heinrich J, Balleisen L, Schulte H, Assmann G, Van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Atheroscler Thromb 1994; 14: 54-59.
3. Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of cross-linked fibrin. Biochem Biophys Acta 1973; 295: 308-313.
4. Lip GYH, Lowe GDO. Fibrin D dimer: a useful clinical marker of thrombogenesis. Clin Sci 1995; 89: 205-214.
5. Lowe GDO, Rumley A, Balendra R, Lee AJ, Tunstall-Pedoe HD. Blood rheology and haemostasis in survivors of premature myocardial infarction: a case-control study. Thromb Haemost 1993; 69: 796.
6. Woodburn KR, Lowe GDO, Rumley A, Love J, Pollock JG. Relation of haemostatic, fibrinolytic and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995;14: 346-352.
7. Smith FB, Lee AJ, Fowkes FGR, Rumley A, Lowe GDO. Smoking, haemostatic factors and the severity of aorto-iliac and femoro-popliteal disease. Thromb Haemost 1996; 75: 19-24.
8. Fowkes FGR, Lowe GDO, Housley E, et al. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet 1993; 342: 84-86.
9. Woodburn KR, Rumley A, Lowe GDO, Love JG, Murray GD, Pollock JG. Clinical, biochemical and rheologic factors affecting the outcome of infra-inguinal bypass grafting. J Vasc Surg 1996; 24: 639-646.
10. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the caerphilly study. Thromb Haemost 1998; 79: 129-133.
11. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J 1995; 73: 527-533.
12. Lassila R, Peltonen S, Lepantalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb 1993; 13: 1738-1742.
13. Nieuwenhuizen W. Biochemistry and measurement of fibrinogen. Eur Heart J 1995; 16 (Suppl A): 6-10.
14. Chung DW, Davie EW. γ and γ′ chains of human fibrinogen are produced by alternative mRNA processing. Biochemistry 1984; 23: 4232-1236.
15. Lawrence SO, Wright TW, Francis CW, Fay PJ, Haidaris PJ. Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. Blood 1993; 82: 2406-2413
16. Haidaris PJ, Peerschke EI, Marder VJ, Francis CW. The C-terminal sequences of the γ 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. Blood 1989 Nov 15; 74: 2437-2444.
17. Haidaris PJ, Francis CW, Sporn LA, Arvan DS, Collichio FA, Marder VJ. Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of γ chain-variant polypeptides. Blood 1989; 74: 743-750.
18. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84: 1320-1324.
19. Weissel JW, Nagaswami C, Vilaire G, Bennett JS. Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 1992; 267: 16637-16643.
20. Kloczewiak M, Timmons ST, Lukas TJ, Hawiger J. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain. Biochemist, 1984; 23: 1767-1774.
21. Hettasch JM, Bolyard MG, Lord ST. The residues AGDV of recombinant gamma chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost 1992; 68: 701-706.
22. Farrel DH, Thiagarajan P, Chung DW, Davie EW. Role of fibrinogen alpha and gamma chain sites in platelet aggregation. Proc Natl Acad Sci USA, 1992; 89: 10729-10732.
23. Gartner TK, Ogilvie ML. Peptides and monoclonal antibodies which bind to platelet glycoproteins IIb and/or IIIa inhibit clot retraction. Thromb Res 1988; 49: 43-53.
24. Tuszynski GP, Kornecki E, Cierniewski C, et al. Beta 3 integrin-mediated fibrin clot retraction by nucleated cells: differing behavior of alpha IIb beta 3 and alpha v beta 3. J Biol Chem 1984; 259: 5247-5254.
25. ChenY, O'Toole TE, Leong L, Liu B, Diaz-Gonzalez F, Ginsberg MH. Beta 3 integrin-mediated fibrin clot retraction by nucleated cells: differing behavior of alpha IIb beta 3 and alpha v beta 3. Blood 1995; 86: 2606-2615.
26. Rooney MM, Parise LV, Lord ST. Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen γ chain C terminus. J Biol Chem 1996; 271: 8553-8555.
27. Falls LA, Farrell DH. Resistance of γA/γ′ fibrin clots to fibrinolysis. J Biol Chem 1997; 272: 14251-14256.
28. Boisseau ME, Mazoyer E, Ripoll L, Drouet L. Does ticlopidine treatment lower plasma fibrinogen? A review of the literature Clin Hemorheol, 1994; 14: 171-180.
29. Hass WK, Easton JD, Adams HP, et al. for the Ticlopidin Aspirin Stroke Study Group. Randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1978; 299: 53-59.
30. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998; 97: 5-9.